#USA #Nashville #Petauri #Pharmaceutical Services #MM+M

Petauri Celebrates Inclusion in MM+M Agency 100 for 2026

Petauri, a dynamic player in the pharmaceutical services sector, proudly announced its recognition as part of the MM+M Agency 100 for 2026, a prestigious annual listing that acknowledges the leading healthcare marketing firms across North America. This honor signifies a milestone in Petauri’s journey, as it continues to carve its niche with impressive growth metrics and a commitment to impactful service delivery.

Founded by Dan Renick, Petauri operates with a clear mission: to streamline the complexities in market access and medical communications within the pharmaceutical and biotech industries. Its remarkable performance has earned the company a noteworthy 32% growth year-over-year, showcasing its resilience and ability to adapt to an ever-evolving healthcare landscape.

Delivering Tailored Solutions with Impact

Petauri’s strength lies in its integrated service model, which is finely tuned to guide clients through various challenges that arise in the pharmaceutical landscape. The firm has extended its services to nearly 300 organizations in 2025 alone, welcoming over 100 new clients into its portfolio.

CEO Dan Renick explains, "When I talk about Petauri, I often start by outlining what we choose not to do. We specifically focus on areas where our capabilities truly shine, ensuring that we offer unmatched expertise and deliver real-world impact for our clients."

This approach places a strong emphasis on crucial areas such as Health Economics and Outcomes Research (HEOR), payer market access strategies, medical communications, healthcare system engagement, and Medicaid access consulting. These sectors have gained increasing importance as the healthcare ecosystem grows more intricate and regulatory pressures mount.

Petauri has also made significant strides by incorporating Artia Solutions into its platform, which enhances its capacity to support clients through the complete spectrum of access channels. As scrutiny and stricter policies from payers intensify, the need for a cohesive, system-level strategy becomes paramount. Petauri’s comprehensive set of capabilities equips it to meet this demand effectively.

Renick highlights the growing need for partners adept in translating complex data into actionable insights, stating, "As innovation surges, especially within rare and orphan diseases, experienced teams that can distill intricate data into clinically relevant narratives are invaluable."

Petauri Advance’s medical communications teams feature extensive knowledge in specialized therapeutic areas like oncology, hematology, immunology, and neuroscience, marking them as essential contributors as scientific developments rapidly evolve.

Recognizing a Strong Corporate Culture

The acknowledgment from MM+M comes on the heels of Petauri’s certification as a Great Place to Work®, which reflects the healthy internal culture being fostered alongside its external achievements.
Lauren Gonzalez, VP of Human Resources, remarks, "It’s incredibly gratifying to see our organization acknowledged in the market while also recognizing that our evolving corporate culture resonates well with our team members. Our people are indeed our greatest asset, and their dedication plays a crucial role in making Petauri what it is today."

As Petauri continues its upward trajectory, its unwavering focus remains on aiding life sciences companies in navigating complex industry landscapes, demonstrating both economic and clinical value, with the ultimate aim of facilitating timely patient access to innovative therapies.

About Petauri

Based in Nashville, Tennessee, Petauri is a purpose-driven pharmaceutical services platform committed to enhancing patient outcomes through strategic partnerships. Established in 2023 with support from Oak Hill Capital, Petauri is on a mission to launch and acquire best-in-class companies with expertise spanning global market access, medical affairs, commercialization support, patient services, and analytics.
The organization has built a robust framework by integrating multiple platforms under its banner, including Petauri Advisors and The Kinetix Group, enabling it to serve a diverse array of pharmaceutical and life sciences clients effectively.
With a planned investment exceeding $250 million from Oak Hill, Petauri is set to redefine excellence in pharmaceutical services, ensuring that the scientific and societal value of medical advancements is widely acknowledged and accessible.

For additional insights, please visit www.petauri.com.